Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 7/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | IL1RN | P18510 | 1/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.43 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.43 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.43 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17598384 | 1.00 | CACNA1B (0.51) | CACNA1BMMEACECPA1ACE2 | |
| SCHEMBL7369240 | 0.93 | MME (0.47) | CACNA1BMMEACECPA1ACE2 | |
| SCHEMBL7399618 | 0.92 | CACNA1B (0.52) | CACNA1BMMEACECPA1ACE2 | |
| SCHEMBL7367928 | 0.92 | MME (0.46) | CACNA1BMMEACECPA1ACE2 | |
| SCHEMBL5833387 | 0.89 | YAP1 (0.44) | CACNA1BMMEACECPA1ACE2 | |
| SCHEMBL7405818 | 0.89 | CACNA1B (0.49) | CACNA1BMMEACECPA1ACE2 | |
| SCHEMBL7409019 | 0.87 | MME (0.54) | CACNA1BMMEACECPA1ACE2 | |
| SCHEMBL5833569 | 0.87 | GPR132 (0.46) | CACNA1BMMEACECPA1ACE2 | |
| SCHEMBL5833222 | 0.86 | REN (0.46) | CACNA1BMMEACECPA1ACE2 | |
| SCHEMBL7369445 | 0.85 | MME (0.52) | CACNA1BMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | CACNA1B 33/4885MME 444/4885ACE 3456/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | CACNA1B 1/4885MME 935/4885ACE 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.